Key Takeaways
- • Novanta Inc. announced the acquisition of Riverpoint Medical from private equity firm Arlington Capital Partners for up to $1.45 billion, expanding its medical device portfolio.
- • The transaction was steered by three major law firms: Ropes & Gray LLP and King & Spalding LLP advising Novanta, while Goodwin Procter LLP represented Riverpoint Medical.
- • The deal structure includes potential earnout or contingent consideration elements, as indicated by the "up to" valuation language, suggesting performance-based payments beyond an initial purchase price.
- • This acquisition reflects continued consolidation activity in the medical technology and medical device sector, with established medtech platforms acquiring specialized device manufacturers.
Summary
Novanta Inc., a medical technology provider, announced on June 9, 2026, its plan to acquire Riverpoint Medical, a medical device maker currently held by private equity firm Arlington Capital Partners, in a transaction valued at up to $1.45 billion. The deal represents a significant consolidation move within the medical device manufacturing sector and underscores ongoing M&A activity in healthcare technology.
The transaction was facilitated by three prominent law firms, signaling the complexity and scale of the transaction. Novanta retained Ropes & Gray LLP and King & Spalding LLP as its legal advisors, while Riverpoint Medical and its seller Arlington Capital Partners were represented by Goodwin Procter LLP. The involvement of multiple top-tier legal counsel indicates substantial deal complexity, likely involving regulatory considerations, representations and warranties, and integration planning typical of large healthcare acquisitions.
The "up to $1.45 billion" valuation suggests a transaction structure incorporating contingent consideration, earnout provisions, or other performance-based payment mechanisms tied to post-closing milestones or financial targets. This structure is common in acquisitions of specialized medical device manufacturers, where future revenue realization or product development success may influence final consideration.
The acquisition reflects broader consolidation trends in medtech, where larger platform companies expand capabilities and market reach through targeted acquisitions of specialized device makers. For Arlington Capital Partners, the transaction represents an exit opportunity, while Novanta gains access to Riverpoint Medical's product portfolio and market position within the medical device space.
The transaction was facilitated by three prominent law firms, signaling the complexity and scale of the transaction. Novanta retained Ropes & Gray LLP and King & Spalding LLP as its legal advisors, while Riverpoint Medical and its seller Arlington Capital Partners were represented by Goodwin Procter LLP. The involvement of multiple top-tier legal counsel indicates substantial deal complexity, likely involving regulatory considerations, representations and warranties, and integration planning typical of large healthcare acquisitions.
The "up to $1.45 billion" valuation suggests a transaction structure incorporating contingent consideration, earnout provisions, or other performance-based payment mechanisms tied to post-closing milestones or financial targets. This structure is common in acquisitions of specialized medical device manufacturers, where future revenue realization or product development success may influence final consideration.
The acquisition reflects broader consolidation trends in medtech, where larger platform companies expand capabilities and market reach through targeted acquisitions of specialized device makers. For Arlington Capital Partners, the transaction represents an exit opportunity, while Novanta gains access to Riverpoint Medical's product portfolio and market position within the medical device space.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.